“Dangling” Accelerated Approvals in Oncology

descriptionPublicationkeyboard_double_arrow_right Article 06 May 2021 English Publisher:Massachusetts Medical SocietyJournal:New England Journal of Medicine, volume 384 (issn: 0028-4793, eissn: 1533-4406,

Copyright policy )

Authors: Julia A, Beaver; Richard, Pazdur;

doi: 10.1056/nejmp2104846

pmid: 33882220

“Dangling” Accelerated Approvals in Oncology

- Summary
- Subjects
- Metrics

Abstract

“Dangling” Accelerated Approvals in Oncology The FDA recently reevaluated accelerated approvals for 35 oncology indications for anti–programmed death ligand 1 antibodies, revealing that for 10 indi...

Related Organizations

United States Food and Drug Administration
United States

Keywords

Clinical Trials as Topic, United States Food and Drug Administration, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humans, Antineoplastic Agents, Medical Oncology, Drug Approval, B7-H1 Antigen, United States

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	70
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 1%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%